420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier.
The agreement with Roche Products (New Zealand) includes funding three new treatments, as well as widened access to one currently funded treatment.
From today there will be one funded brand of lamotrigine - a medicine used to treat epilepsy and some mental health conditions, including bipolar disorder.
There are several suppliers that make lamotrigine – each with their own brand. PHARMAC has decided to change from funding three different brands (Lamictal, Arrow-Lamotrigine and Logem) to funding the Logem brand only.
PHARMAC has reached a deal with pharmaceutical companies for three new medicines to treat ovarian cancer, breast cancer and leukaemia.
PHARMAC has distributed over 1.26 million doses of the influenza vaccine this winter.
The 2019 Tapuhi Kaitiaki Awards, jointly awarded by PHARMAC and Te Rūnanga o Aotearoa/New Zealand Nurses Organisation (NZNO) and presented in August will both celebrate and support Māori nurses to continue in their studies and improve their clinical practice. Nominations/applications are now open.
Over 1500 New Zealanders have started a new hepatitis C treatment in the last three months that could dramatically change their lives.
PHARMAC has today provided haemophilia patients fully funded access to new innovative treatment options which will make a major difference to their lives, PHARMAC Director of Operations Lisa Williams says.
An overhaul of PHARMAC’s decision-making process will give better insight into what medicines are - and are not - being actively considered for funding, Chief Executive, Sarah Fitt says.
Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February 2019, after PHARMAC funds a new treatment.
Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has reached with Novartis, which makes more funded medicines available for a wide range of health conditions.
PHARMAC is celebrating the formation of New Zealand’s first Pacific Pharmacists’ Association. PHARMAC Chief Executive, Sarah Fitt, says PHARMAC is proud to support Pacific pharmacists working...
PHARMAC and Te Pōari o Te Rūnanga o Āotearoa and their Tiriti partner Tōpūtanga Tapuhi Kaitiaki o Āotearoa (NZNO) are pleased to announce the inaugural recipients of the Tapuhi Katiaki Awards.
If you get a cold or flu this winter, taking antibiotics won’t fix it.
PHARMAC is progressing work aimed at improving funded access to medicines for rare disorders.
PHARMAC is pleased to provide another treatment option for patients with severe osteoporosis following the funding of denosumab, brand name Prolia, from 1 July 2018.
PHARMAC and Te Pōari o Te Rūnanga o Aotearoa/ Tōpūtanga Tapuhi Kaitiaki o Aotearoa/New Zealand Nursing Organisation (NZNO) are pleased to announce the launch of the Tapuhi Kaitiaki Awards (Māori Nurses Awards).
This year, PHARMAC is reviewing the way we seek and incorporate the consumer voice in our work, and is asking people about how we could improve input from, or engagement with, them.
PHARMAC is pleased that the Government has announced an uplift in PHARMAC’s funding.
Thousands of New Zealanders will benefit from advances in treatment as a result of two PHARMAC funding decisions. The first decision is to fund a medication for treating a degenerative eye condition, and the second is to fund another oral anticoagulant option for the prevention of strokes and the prevention or treatment of blood clots.
PHARMAC and Ngā Kaitiaki o Te Puna Rongoā ō Āotearoa (Māori Pharmacists Association) recently celebrated the 10th year of the Hiwinui Heke, Māori Pharmacy Student Scholarships in Rotorua.